Literature DB >> 879108

Thymidine-dependent strain of Salmonella oslo selected by trimethoprim-sulfamethoxazole therapy.

L R McCarthy, H Chmel, G Bell, D Armstrong.   

Abstract

A case report describing the isolation of a multiple-drug-resistant strain of Salmonella oslo from urine and stool specimens is presented. After ten days of trimethoprim-sulfamethoxazole therapy, a second strain of Salmonella oslo was isolated from another stool specimen. The second strain was determined to be a thymidine-requiring organism. The significance of this thymidine-requiring strain is described.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 879108     DOI： 10.1093/ajcp/68.2.307

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN： 0002-9173            Impact factor:   2.493


  4 in total

1.  Infection caused by thymidine-requiring, trimethoprim-resistant bacteria.

Authors:  C H King; D M Shlaes; M J Dul
Journal:  J Clin Microbiol       Date:  1983-07       Impact factor: 5.948

2.  In vivo mutations of thymidylate synthase (encoded by thyA) are responsible for thymidine dependency in clinical small-colony variants of Staphylococcus aureus.

Authors:  Indranil Chatterjee; Andre Kriegeskorte; Andreas Fischer; Susanne Deiwick; Nadine Theimann; Richard A Proctor; Georg Peters; Mathias Herrmann; Barbara C Kahl
Journal:  J Bacteriol       Date:  2007-09-28       Impact factor: 3.490

3.  Pneumonia caused by a previously undescribed bacterium.

Authors:  R L Hopfer; K Mills; V Fainstein; H E Fischer; M P Luna
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

4.  Inactivation of thyA in Staphylococcus aureus attenuates virulence and has a strong impact on metabolism and virulence gene expression.

Authors:  Andre Kriegeskorte; Desiree Block; Mike Drescher; Nadine Windmüller; Alexander Mellmann; Cathrin Baum; Claudia Neumann; Nicola Ivan Lorè; Alessandra Bragonzi; Eva Liebau; Patrick Hertel; Jochen Seggewiss; Karsten Becker; Richard A Proctor; Georg Peters; Barbara C Kahl
Journal:  MBio       Date:  2014-07-29       Impact factor: 7.867
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.